Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series

In conclusion, our study suggests that nivolumab monotherapy is well-tolerated and may be an effective salvage therapy for BRCA mutation carriers with recurrent epithelial ovarian, fallopian tubal, and primary peritoneal cancers.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research